Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Amphstar Pharmaceuticals (AMPH)

Amphastar Q4 revenue rises 5% to $186.5 million; GAAP diluted EPS $0.74

Positive Impact 3 of 5 earnings Written later

Amphastar Pharmaceuticals reported fourth-quarter and full-year 2024 results on February 27, 2025. Net revenues rose 5% in the quarter and 14% for the year, and GAAP diluted EPS increased from the prior-year periods, though fourth-quarter gross margin fell to 46.5% from 54.0%.

Key points

  • Q4 net revenues were $186.5 million, up from $178.1 million; GAAP diluted EPS was $0.74 versus $0.68 and adjusted non-GAAP diluted EPS was $0.92 versus $0.88.
  • Full-year net revenues were $732.0 million, up from $644.4 million; GAAP diluted EPS was $3.06 versus $2.60.
  • Q4 gross margin was 46.5% versus 54.0%, mainly due to lower other revenues after the Lilly Transition Service Agreement with Lilly expired in Q4 2024; BAQSIMI product revenues were $41.8 million in the quarter.

The filing

CompanyAmphstar Pharmaceuticals (AMPH)
Form8-K, current report
Filed with the SECFeb 27, 2025, 4:33 PM ET
Accession number0001297184-25-000003

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.